Cargando…
Efficacy and Treatment Satisfaction of Different Systemic Therapies in Children and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World Study
For the treatment of moderate-to-severe atopic dermatitis in children and adolescents, the monoclonal antibody dupilumab and the selective JAK-1 inhibitor upadacitinib are two modern systemic therapies approved for long-term treatment. Both drugs have demonstrated high efficacy in randomized control...
Autores principales: | Kiefer, Sebastian, König, Anke, Gerger, Viviane, Rummenigge, Christine, Müller, Anne Christine, Jung, Thomas, Frank, Alexandra, Tassopoulos, Georgios, Laurent, Emilie, Kaufmann, Roland, Pinter, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917393/ https://www.ncbi.nlm.nih.gov/pubmed/36769820 http://dx.doi.org/10.3390/jcm12031175 |
Ejemplares similares
-
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
por: Bernardo, Diana, et al.
Publicado: (2023) -
Real-World Treatment Patterns and Treatment Benefits among Adult Patients with Atopic Dermatitis: Results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey
por: AUGUSTIN, Matthias, et al.
Publicado: (2022) -
Tolerability and Efficacy of a Medical Device Repairing Emollient Cream in Children and Adults with Mild to Moderate Atopic Dermatitis
por: Pinter, Andreas, et al.
Publicado: (2019) -
Oxidative stress as a treatment target in atopic dermatitis: The role of furfuryl palmitate in mild-to-moderate atopic dermatitis
por: Hebert, Adelaide A.
Publicado: (2020) -
Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)